Drug Trial Radar · NCT06946225
ACTengine® IMA203 Combined With mRNA-4203
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Jul 25, 2025
Primary completion
Aug 2029
Study completion Aug 2029
Sponsor
- Lead sponsor
- Immatics US, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- ModernaTX, Inc.
- First posted
- Apr 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).
Conditions
- Cutaneous Melanoma
- Synovial Sarcoma
Interventions
IMA203Biological
Following non-myeloablative chemotherapy for lymphodepletion (LD) with fludarabine (FLU) and cyclophosphamide (CY), participants will receive a single infusion of IMA203 on Day 1 and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion.
mRNA-4203Biological
mRNA-4203 will be administered starting on Day 15 after IMA203 infusion at the earliest. mRNA-4203 will be given for 12 cycles (28 day cycle length); during Cycle 1 it will be given on Day 1 and Day 15 and in Cycles 2-12 it will be given on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose-limiting toxicities (DLTs)Time frame: one year post infusion of IMA203
- Number of treatment emergent adverse events (AEs), AEs of special interest, serious AEs (SAEs), changes in laboratory parameters and vital signs, and frequency of dose interruptions, reductions and discontinuationsTime frame: one year post infusion of IMA203
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.